about
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerBisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceCollapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literatureHuman isoprenoid synthase enzymes as therapeutic targetsDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsWhere Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Bisphosphonates in breast cancerZoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysisCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaRandomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivoPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database.FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicinInfluence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivoZoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Aromatase inhibitors-induced bone loss in early breast cancer.The microenvironment matters: estrogen deficiency fuels cancer bone metastasesPharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.The best of both worlds - managing the cancer, saving the bone.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Pathophysiology of Bone Remodelling and Current Therapeutic Approaches.Breast Cancer 2012 - New AspectsEffects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancerBisphosphonates inactivate human EGFRs to exert antitumor actions.Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitorsReal-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancerAddressing the controversy: do bisphosphonates directly affect primary tumors?Adjuvant bisphosphonates in breast cancer treatmentEffect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.Bone remodeling markers and bone metastases: From cancer research to clinical implicationsLatest advances in the medical treatment of cancer: a 2011 snapshot.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
P2860
Q21132670-94A373C0-734D-4D0B-867A-36D3DFDC2B07Q26746212-852C8A5C-10B1-4FB8-A1BA-1C14FABF3EFAQ26795493-50B1217A-EA3B-4508-BC2C-7DC230618EB7Q26801348-4D2C2F5E-207C-4F9A-A728-6B78930E8AEBQ26822639-28E13A1C-540B-4F43-B973-93B846F27D03Q26824762-C1DBCADB-11D6-4936-A9AD-4B79FB30F428Q26849473-DEFF549B-D41E-45FF-8F67-E225722B084BQ26859326-EEA32270-6002-4C81-AC47-9FAE7018E37DQ26861745-0B82F85C-1FBC-44A0-A56F-E8C7740DB2D2Q27011658-66EFC1F0-7BA7-40D1-B9B5-1DE6CE7A92A7Q28081996-45170D76-80B3-4AEC-9CF9-892FCCE7FEC6Q28551320-543D45A5-BEDB-490C-A2B4-B722E70DE1A4Q30275126-971DFE58-7E31-47ED-BA1F-80E424A6C839Q30543788-CB35263B-A449-4818-AD83-2A952004A6ADQ31108809-33758526-1948-42B4-8365-C30705BCA546Q31150676-68C85594-7583-4B02-8422-34755DAA9B89Q33422353-B0DCF3F2-E19C-45CA-8F74-F945B20DC904Q33587199-65680CA1-685A-408D-B967-B7DFB634C392Q33692900-D87652AD-5D95-449F-B51C-D11D4223D9F4Q33739204-424F0A39-A6CF-4DEF-B791-ECA041653FE1Q33752867-740C5551-7995-4374-83D9-8BE686A5F87DQ33772299-79B2B68F-5854-4E70-920C-E43E4137DD1EQ33882079-16DEAFB6-7063-41A8-8B04-312C978CA721Q33920055-70CB3A3F-453D-49B8-AF25-F5BC97774B2AQ34042715-CD29B0F7-537D-4B6D-B5ED-6348ADADF21FQ34209614-FCC0DFD2-CABE-4C11-8AFF-79200B86CA02Q34209663-8D7701D2-7C72-4575-BDB9-F4830F8BC13AQ34581699-74EC0C90-1AE0-49D5-8EFD-13A380AB0D65Q34583705-8DD4BF7D-3CDD-4D3C-8244-FEAD7AA0166FQ34655579-8144F236-C8A1-457A-A2C6-3F8D53B7BC8AQ34752800-06471A7B-5095-4E8A-9375-FB99DC05C50AQ34752876-B439D0D9-43D9-4235-8B08-2B1F36E1F340Q34779663-EDF10D74-F7BB-404C-9043-9D9A3BFAD9D4Q34945422-EC0773E3-2F76-440C-B0DC-41A7097182FAQ34970986-9628E742-8587-4981-A0B9-B8371C8D06EDQ35066934-056488B0-9F68-4962-86D1-9AD867AAE870Q35431110-F77382B7-965F-4F74-AB2E-49477FB312ABQ35531006-C73699EE-D6DC-456D-8BF2-D6FEA77710D7Q35628127-CEC40747-FD0B-41A6-92CE-751D0C259120Q35667196-0AF83A1D-A6CB-4EF4-A504-2A4D38D56DB1
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Breast-cancer adjuvant therapy with zoledronic acid.
@en
Breast-cancer adjuvant therapy with zoledronic acid.
@en-gb
Breast-cancer adjuvant therapy with zoledronic acid.
@nl
type
label
Breast-cancer adjuvant therapy with zoledronic acid.
@en
Breast-cancer adjuvant therapy with zoledronic acid.
@en-gb
Breast-cancer adjuvant therapy with zoledronic acid.
@nl
prefLabel
Breast-cancer adjuvant therapy with zoledronic acid.
@en
Breast-cancer adjuvant therapy with zoledronic acid.
@en-gb
Breast-cancer adjuvant therapy with zoledronic acid.
@nl
P2093
P356
P1476
Breast-cancer adjuvant therapy with zoledronic acid.
@en
P2093
AZURE Investigators
Claire Davies
Claire Gaunt
David Cameron
David Dodwell
Diana Ritchie
Jennifer Peterson
Julia Pugh
Maccon Keane
Miguel Gil
P304
P356
10.1056/NEJMOA1105195
P407
P5530
P577
2011-09-25T00:00:00Z
P5875
P6179
1016139121